Go with AM/PM
Drug Policy 36 , 141147 (2016)
Side Effects & Safety Typical first-cycle side effects: Weeks 1-2: mild water retention, vivid dreams, light head/warmth after injection Weeks 3-4: occasional joint stiffness, improved sleep quality, slight appetite increase overnight Weeks 5-8: adaptation phase most side effects fade, body composition changes visible Clinical discontinuation signals (trial-reported): Clinical participants in tesamorelin studies were discontinued upon experiencing: Persistent headaches with visual changes (intracranial pressure marker in trial monitoring protocols) Sustained fasting glucose elevation of ~15 mg/dL above baseline Unusual peripheral swelling persisting beyond weeks 1-2 Carpal tunnel symptoms unresponsive to dose titration in community-reported protocols Tesamorelin has been studied at 2mg/day for 6+ months without notable safety signals at therapeutic doses
Large glucose swings, visceral adiposity, fatty liver, and elevated fasting insulin may all signal a metabolic environment that is less favorable for long-term cognitive health
Da Obstipation bereits eines der Symptome der Parkinson-Krankheit ist, sei es bedauerlich, dass das Medikament zur Behandlung der Symptome selbst die Darmmotilitt aufgrund der bakteriellen Metabolisierung des Darms weiter verringern kann
PubMed Central, doi:10.4137/EHI.S38343
